The Promise of Scientific Partnerships with People on the Spectrum
Five collaborations involving autistic scientists and experts are advancing autism research, from lending support for theories of the condition to shoring up trials of new treatments.
The Promise of Scientific Partnerships with People on the Spectrum
The Promise of Scientific Partnerships with People on the Spectrum
Five collaborations involving autistic scientists and experts are advancing autism research, from lending support for theories of the condition to shoring up trials of new treatments.
Five collaborations involving autistic scientists and experts are advancing autism research, from lending support for theories of the condition to shoring up trials of new treatments.
Aripiprazole, marketed as Abilify, is widely thought to be safer than risperidone, the only other drug approved for use in autistic children. A decade’s worth of data suggests that is not true.
Independent scientists say the original analysis is flawed; the authors stand by their work and are seeking outside statisticians to reanalyze the data.
Signaling imbalance, driven by too much excitatory activity, may be a consequence of whatever brain changes lead to autism rather than a cause of the condition.